Epilepsy Therapeutics Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

Epilepsy is a severe neurological disorder with unpredictable seizures. Epilepsy affects millions of people all over the world and it is the one of the most common neurological disorder. Seizures may be classified as generalized seizures, focal seizures, and other seizures. Among these, focal seizures are the most common type of seizures. Generalized seizures comprise tonic seizures, myoclonic seizures, absences, clonic seizures, and atonic seizures. Focal seizures involve complex partial seizures and secondary generalized clonic/tonic seizures (sGCTS). When a group of nerve cells or neurons in the brain send wrong or multiple signals to the body, at that time seizures occur. The growing prevalence of neurological disorders globally is expected to propel the growth of the global market over the coming years. Moreover, increasing awareness about treatment and diagnostics of neurological disorders and easy availability of drugs in the developed market is expected to propel the growth of the market in the near future.

The global epilepsy therapeutics market is segmented as product type, distribution channel, and by geography. Based on product type, the epilepsy therapeutics market is segmented into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics. On the basis of the distribution channel, the epilepsy therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

North America accounted for the dominant share in the global market for epilepsy therapeutics in 2017 and is anticipated to continue with its regional supremacy over the forthcoming years as well. For epilepsy drugs, North America is the most mature market and hence is expected to grow slowly over the forecast period. The high government support, strong research and development platform, and strong pipeline for epilepsy drugs for the development of next-generation anti-epileptic drugs are the key factors contributing for the high share of North America epilepsy therapeutics market.

Asia Pacific is expected to register the highest CAGR in the global epilepsy therapeutics market in the coming years. The growing awareness about advanced anti-epileptic drug treatment in emerging economies is expected to boost the growth of Asia Pacific epilepsy therapeutics market over the forecast period.  

Some of the key players in the epilepsy therapeutics market are Eisai Co., Ltd., GlaxoSmithKline, Pfizer Inc., UCB S.A., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceutical, Abbott, Novartis AG, and Shire. The growing prevalence of epilepsy and increasing competition among the key players in the market for the development of advanced drugs is expected to propel the growth of the market over the coming years.